Financial Performance - Carlyle reported income before provision for income taxes of $441 million, with a margin of 280% for Q2 2025[3] - Net income attributable to The Carlyle Group Inc common stockholders was $320 million, or $087 per share on a diluted basis for Q2 2025[13] - Distributable Earnings (DE) were $431 million for Q2 2025, or $091 per common share on a post-tax basis[18] - Fee Related Earnings (FRE) were $323 million for Q2 2025[18] - Realized Net Performance Revenues were $88 million for Q2 2025[18] Assets Under Management (AUM) - Total Assets Under Management reached $465 billion as of June 30, 2025, a 7% increase year-over-year[6, 18] - Fee-earning Assets Under Management totaled $325 billion, up 6% year-over-year[18] - Perpetual Capital Fee-earning AUM was $101 billion, representing 31% of total Fee-earning AUM[18] Capital Management - A quarterly dividend of $035 per common share was declared, payable on August 28, 2025[4, 18] - The company repurchased or withheld 23 million shares of common stock in Q2 2025, totaling $104 million[18] - As of June 30, 2025, $06 billion of repurchase capacity remained under the $14 billion repurchase authorization[18]

Second Quarter 2025 Performance - Second quarter revenue reached $148 million, with organic revenue growth of 6%[13] - Adjusted Earnings Per Share (EPS) increased 31% to $0.21, and Adjusted EBITDA margin increased 23%[13] - Surgical Solutions revenue increased 11% compared to the prior year quarter, driven by double-digit growth in Ultrasonics[39] - Restorative Therapies revenue declined 32% compared to the prior year quarter due to the divestiture of the Advanced Rehabilitation Business, while EXOGEN grew 11%[39] - Pain Treatments revenue increased 1% compared to the prior year quarter[39] Financial Metrics and Guidance - Adjusted Gross Margin increased 50 basis points due to improved product mix[40] - The company ended the second quarter with $33 million in cash and $341 million in debt outstanding[48] - Cash from operations was an inflow of $26 million in the second quarter[48] - The company reaffirms its 2025 financial guidance, projecting net sales in the range of $560 million to $570 million, representing organic growth of 6% to 8%[52] - Adjusted EBITDA is expected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share is projected to be in the range of $0.64 to $0.68[52] Strategic Initiatives and Future Outlook - The company received FDA 510(k) clearance for StimTrial and TalisMann, Peripheral Nerve Stimulation (PNS) products, targeting the chronic peripheral pain market[18, 20] - The PNS market is estimated to be growing above 20% annually in the U S and is expected to exceed $500 million by 2029, with an expected total addressable market of approximately $2 billion[20] - The company plans to invest in a direct sales force in the second half of 2025 and expects TalisMann and StimTrial to potentially generate $100 million or more of revenue[27] - The company forecasts at least 100 basis points of Adjusted EBITDA margin expansion in 2025[30] - The company expects cash from operations in 2025 to nearly double compared to 2024 and expects to reduce net leverage to below 2 5 times by the end of 2025[30, 48]

Financial Performance - Total revenue for Q2 2025 reached $489.93 million, reflecting a 12% year-over-year increase[66] - Creative Subscriptions Annualized Recurring Revenue (ARR) stood at approximately $1.4 billion as of June 30, 2025, a 10% increase year-over-year[11, 24] - Total bookings for Q2 2025 amounted to $509.92 million, representing an 11% year-over-year growth[66] - The company anticipates generating a free cash flow (FCF) margin of 30-31% in 2025[58] - Non-GAAP gross margin was 70% in Q2 2025[67] Business Segments - Partners revenue for Q2 2025 was $183.32 million, a 24% increase year-over-year[11, 73] - Transaction revenue for Q2 2025 reached $63.55 million, an 18% increase year-over-year[11, 73] User Cohorts and Marketing - New cohort bookings growth accelerated to 14% in Q2 2025 over the Q2 2024 cohort[36] - The company estimates approximately $18.4 billion in expected future bookings over the next 10 years from existing cohorts[45] Geographic Reach - Approximately 40% of the company's revenue comes from outside North America[11] Acquisition - Wix acquired Base44 in June 2025, which is projected to generate $40-$50 million of ARR by the end of 2025[17]

Second Quarter 2025 Financial Results Call 1 Disclaimer Certain statements in this presentation may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements generally relate to future events or Holley's future financial or operating performance. For example, projections of future revenue and adjusted EBITDA and other metrics, along with statements regarding the impact of or ...

Financial Performance - Q2 2025 - Net sales reached $60 billion, a 102% increase compared to the same period last year[12] - Gross profit was $12 billion, up by 49%, but the gross profit margin decreased by 100 basis points to 208%[12] - Operating income decreased by 30% to $420 million, while non-GAAP operating income increased by 18% to $520 million[12] - Net income decreased by 35% to $271 million, but non-GAAP net income per diluted share increased by 39% to $260[12] Sales by Channel - Q2 2025 - Corporate sales increased by 176% to $25815 million[13] - Small Business sales increased by 126% to $4313 million[13] - Healthcare sales increased significantly by 241% to $7285 million[13] - Education sales experienced a decline of 109%, reaching $9067 million[13] Liquidity and Cash Flow - Total debt was $56327 million as of June 30, 2025[16] - Free cash flow for the quarter was $1334 million, and adjusted free cash flow was $2101 million[18] - The company returned $515 million year-to-date to shareholders through share repurchases and dividends[19] 2025 Outlook - The company anticipates U S IT growth plus a premium target of approximately 200 to 300 basis points[21] - The company expects low-to-mid single-digit growth in gross profit[21] - The company projects low-single-digit growth in non-GAAP net income per diluted share[21]

Earnings Conference Call Presentation Q3 FY25 August 6, 2025 Pro Forma and Non-GAAP Measures This presentation includes the presentation and discussion of pro forma financial information that incorporates the results of Jacobs' Critical Mission Solutions and Cyber & Intelligence businesses ("CMS") prepared in accordance with the requirements of Article 11 of Regulation S-X. This presentation also includes the presentation and discussion of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjust ...

Defining the next era of commerce August 6, 2025 Advisories This presentation contains forward-looking statements and forward looking information (collectively, "forward-looking statements") that are based on our management's current estimates, beliefs and assumptions and management's perception of historic trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. These statements may be identified by words such as "expect ...

Valens Semiconductor (NYSE:VLN) August 2025 GAAP and non-GAAP Measures Certain statements in this presentation (this "Presentation") are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that pred ...

Financial Performance - Consolidated net sales increased by approximately 1% year-over-year to ~$3.7 billion in Q3 FY25[11] - Adjusted EBITDA increased by $24 million year-over-year to $226 million in Q3 FY25, with a margin increase of 60 bps[11, 12] - Free cash flow was $115 million in Q3 FY25[11] - The company returned $50 million to shareholders through share repurchases in Q3, bringing the year-to-date total to $75 million, representing approximately 4% of shares outstanding[11, 12] - Adient is raising its FY25 revenue and EBITDA guidance[12] Regional Performance - Americas sales outperformed the market by 300 bps due to favorable volume/mix and full run-rate of key programs[32] - EMEA sales underperformed the broader market mainly due to customer mix and intentional portfolio actions[32] - Asia sales growth outpaced the broader market by 700 bps, driven by customer launches reaching full production volumes[32] Debt and Capital Structure - Cash balance was $860 million as of June 30, 2025[11] - Gross debt was approximately $2.4 billion and net debt was approximately $1.5 billion[11] - Net leverage ratio on a trailing twelve-month basis is 1.7x, within the targeted range of 1.5x-2.0x[44] Outlook - Consolidated revenue is expected to be approximately $14.4 billion[46] - Adjusted EBITDA is expected to be approximately $875 million[46] - Capital expenditures are expected to be approximately $150 million-$170 million[46]

Financial Performance - Net sales for Q2 2025 were $330.3 million [8], a decrease of 4.4% compared to $345.5 million in Q2 2024 [44] - Adjusted EBITDA for Q2 2025 was $33.7 million [8], an increase of 22.1% compared to $27.6 million in Q2 2024 [44] - Adjusted EBITDA margin for Q2 2025 was 10.2% [8], an increase of 220 bps compared to 8.0% in Q2 2024 [44] - Adjusted EPS for Q2 2025 was $0.88 [8], an increase of 44.3% compared to $0.61 in Q2 2024 [44] - Free cash flow was $9.0 million in Q2 2025 [8], representing 53.9% of net income [8] Segment Performance - Infrastructure Solutions net sales for Q2 2025 were $204.6 million [47], a decrease of 7.6% compared to $221.4 million in Q2 2024 [47] - Infrastructure Solutions segment operating adjusted EBITDA margin for Q2 2025 was 15.7% [47], an increase of 340 bps compared to 12.3% in Q2 2024 [47] - Materials Solutions net sales for Q2 2025 were $125.7 million [50], an increase of 1.3% compared to $124.1 million in Q2 2024 [50] - Materials Solutions segment operating adjusted EBITDA margin for Q2 2025 was 11.3% [50], an increase of 310 bps compared to 8.2% in Q2 2024 [50] Backlog and Orders - The backlog level is $380.8 million [8]